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Abstract: The current nutritional habits and lifestyles of modern societies favor  
energy overloads and a diminished physical activity, which may produce serious clinical 
disturbances and excessive weight gain. In order to investigate the mechanisms by  
which the environmental factors interact with molecular mechanisms in obesity, a  
pathway analysis was performed to identify genes differentially expressed in subcutaneous 
abdominal adipose tissue (SCAAT) from obese compared to lean male (21–35 year-old) 
subjects living in similar obesogenic conditions: habitual high fat dietary intake and 
moderate physical activity. Genes involved in inflammation (ALCAM, CTSB, C1S,  
YKL-40, MIF, SAA2), extracellular matrix remodeling (MMP9, PALLD), angiogenesis 
(EGFL6, leptin) and oxidative stress (AKR1C3, UCHL1, HSPB7 and NQO1) were 
upregulated; whereas apoptosis, signal transcription (CITED 2 and NR3C1), cell control 
and cell cycle-related genes were downregulated. Interestingly, the expression of some of 
these genes (C1S, SAA2, ALCAM, CTSB, YKL-40 and tenomodulin) was found to be 
associated with some relevant metabolic syndrome features. The obese group showed a 
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general upregulation in the expression of inflammatory, oxidative stress, extracellular 
remodeling and angiogenic genes compared to lean subjects, suggesting that a given 
genetic background in an obesogenic environment could underlie the resistance to gaining 
weight and obesity-associated manifestations. 
Keywords: metabolic syndrome; microarray; inflammation; oxidative stress;  
subcutaneous adipose tissue 
 
1. Introduction 
Inflammation is nowadays considered as a key feature associated to fat accumulation and obesity 
related conditions [1]. This pro-inflammatory status seems to be initially located in white adipose 
tissue, being currently suggested to be largely related to a dysregulation in adipokine secretion, which 
leads to different pathological conditions associated with obesity and metabolic syndrome features 
such as type 2 diabetes and cardiovascular disease [2–4]. Three reasons have been proposed by 
different groups to explain this inflammatory process occurring within adipose tissue: (a) local  
hypoxia [5,6]; (b) endoplasmic reticulum stress [7–9]; and (c) oxidative stress [10–12]. 
The prevalence of obesity is rising worldwide, which is likely to be a consequence of changes in 
modern societies, where easy and cheap availability of high-calorie yielding foods is combined with a 
sedentary lifestyle [13,14]. In this context, it has been suggested that the inflammatory state associated 
with obesity appears to be predominantly triggered by excessive nutrient intake [15] and/or unhealthy 
dietary patterns [16]. Further to this, a human study with almost 3000 people has shown that subjects 
with higher concentrations of inflammatory markers in their blood are more prone to gaining weight [17]. 
However, in this condition of chronic disturbance of metabolic homeostasis, some subjects seem to be 
more resistant to gaining weight and to showing metabolic syndrome manifestations [18,19]. Thus, 
there are consistent evidences from different human studies about the importance of the individual 
genetic background in the fat deposition and in the success of weight loss programs [14,20,21]. 
Indeed, a study carried out in mice revealed that the inflammatory state associated with obesity 
appears to be partly triggered by high fat diet and excessive weight [22]. Furthermore, the composition 
and quantity of the fat content of a meal seems to be directly related to the magnitude of the 
postprandial inflammatory response [23]. In this context, adipose tissue is one of the organs 
responsible for nutrient clearance from blood [24]. Therefore, it is reasonable to suggest a main role of 
inflammation in the vulnerability to obesity and the metabolic syndrome [25,26]. 
Thus, a genetic background favoring a pro-inflammatory status, in the presence of increased food 
availability could underlie the predisposition to develop obesity [27]. In order to clarify differences  
in the functional capacity of the adipose tissue, a pathway analysis was performed to identify 
inflammatory and metabolic genes differentially expressed in obese vs. lean subjects living in similar 
obesogenic conditions that could underlie in the vulnerability to obesity and metabolic syndrome 
development. Indeed, the interest of this trial was the fact that some subjects consuming the same 
amount of fat/energy and showing similar physical activity patterns produced different body weight 
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phenotypes since some of them were obese and others were lean, which could be, at least in part, 
related to differences in the gene expression profile in white adipose tissue. 
2. Results and Discussion 
2.1. Baseline Characteristics of Lean and Obese Subjects 
Descriptive characteristics at baseline of lean and obese subjects with similar habitual dietary intake 
of fat (>40%) and moderate physical activity are reported in Table 1. As expected, waist circumference 
was significantly higher in the obese than in lean subjects. Insulin sensitivity revealed by  
Quantitative Insulin-Sensitivity Check Index (QUICKI) was significantly lower in obese compared to 
lean subjects. The fasting lipid profile including Total Cholesterol and Total Cholesterol/HDL  
(High-Density Lipoprotein)-Cholesterol ratio was significantly higher (p < 0.01) in the obese 
compared to lean persons. The systolic and diastolic blood pressure values were significantly elevated 
(p < 0.01) in the obesity condition. Despite that high fat diet is associated with the occurrence of 
metabolic syndrome manifestations, lean volunteers showed no features of metabolic syndrome. Five 
of the obese volunteers were considered as obese with metabolic syndrome (WHO), based on the 
presence of three or more of the following characteristics according to the National Cholesterol 
Education Program: waist circumference greater than 102 cm; blood pressure of at least 130/85 mmHg; 
serum glucose level of at least 110 mg/dL; serum triacylglycerol level of at least 150 mg/dL; and 
HDL-cholesterol level of less than 40 mg/dL. 
Table 1. Anthropometrical and clinical parameters of volunteers. 
Baseline descriptive characteristics 
Lean (n = 9) Obese (n = 9) 
p value 
Mean SE Mean SE 
Energy (Kcal) 2,766.7 258.7 2799.1 171.4 0.918 
Fat intake (%E) 44.6 2.2 42.5 1.8 0.573 
Physical activity (METs h/week) 17.5 5.1 18.0 4.4 0.945 
Watching TV (METs h/week) 12.2 2.5 10.2 3.2 0.621 
BMI (kg/m2) 23.1 0.4 34.7 1.2 0.000 
Waist circumference (cm) 78.7 1.2 105.7 2.6 0.000 
QUICKI 0.40 0.00 0.35 0.01 0.004 
Triglycerides (mg/dL) 85.0 6.7 142.2 10.6 0.001 
Total Cholesterol (mg/dL) 167.4 17.7 188.5 6.3 0.008 
HDL-Cholesterol (mg/dL) 43.3 1.7 40.0 2.4 0.059 
Total Cholesterol/HDL-C 3.5 0.2 5.0 0.3 0.003 
Systolic BP (mmHg) 122.5 3.6 139.1 2.8 0.002 
Diastolic BP (mmHg) 74.0 2.2 82.8 3.0 0.002 
Abbreviations: BMI: Body mass index; QUICKI, Quantitative Insulin-Sensitivity Check Index;  
HDL, High-Density Lipoprotein; BP, Blood Pressure; MET, Metabolic Equivalent of Task; SE, Standard Error. 
Independent Student’s t-test or Mann-Whitney U-test were performed, as appropriate, depending on the 
results of Kolmogorov-Smirnoff and Shapiro-Wilk normality tests. 
One group of lean subjects that despite showing a high fat intake and moderate physical activity 
remained lean and resistant to weight gain and with no features of metabolic syndrome was identified, 
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which should be attributed to different genetic make-up [18]. The failure of the adipose tissue to buffer 
postprandial lipids due to a metabolic inefficacy, has been suggested as a mechanism triggering 
inflammatory response in adipose tissue [28]. Thus, several studies have recently shown a cross-talk 
between metabolic and immune system and how important this link could be to the development of 
obesity and/or its co-morbidities [29–31]. Mitochondrial dysfunction in adipocytes due to an excessive 
free fatty acid release and local hypoxia, common features in the adipose tissue from obese patients, 
seems to induce insulin resistance and lipotoxicity [32,33]. In fact, the mitochondrion gene ontology (GO) 
category (cellular component) was downregulated in obese compared to lean (p < 0.001). 
2.2. Over-Represented GO Biological Process Categories 
2.2.1. Genes Involved in Inflammation 
Pathway analysis revealed that the most notable class of genes upregulated in subcutaneous 
abdominal adipose tissue (SCAAT) of obese compared to lean subjects concerned the immune 
response (12 genes p < 0.001, Table S1). This category included genes encoding members for the 
Complement system, as C1S, CD163 and CD59; Antigen processing: HLA-DQA1, HLA-DRB4 and 
CTSB; Genes involved in T cell response including: SPP1, DEFA1, SAA1, SAA2 and ALCAM.  
In addition, MIF a chemotactic factor for monocytes/macrophages and YKL-40, a human glycoprotein, 
were also upregulated. In order to validate the results of the microarray, the gene expression 
upregulation of ALCAM, CTSB, C1S, YKL-40, MIF and SAA2 was verified by Real Time-Polymerase 
Chain Reaction (RT-PCR, Table 2). 
Moreover, a downregulation of some similar genes involved in inflammation has been reported 
after weight loss [34], which clearly ameliorates the cardiovascular risk and metabolic syndrome 
features. Furthermore, MIF has been reported to be upregulated in adipocytes exposed to 1% O2 [35]. 
We reported for the first time the upregulation of activated leukocyte-cell adhesion molecule 
(ALCAM), a broadly expressed adhesion molecule of the Ig superfamily, which shows high sequence 
homology with one candidate HDL receptor, HB2-high-density lipoprotein-binding protein 2, one of a 
pair of liver HDL binding proteins [36]. Additionally, we also found that YKL-40 gene expression 
appeared overexpressed. YKL-40 has been identified as a biomarker of inflammation, as it is elevated 
in patients with type 2 diabetes and related to insulin resistance [37] and extracellular matrix (ECM) 
remodeling [38], and is also elevated in cardiovascular disease [39]. Moreover, YKL-40 was described 
as being secreted by adipose tissue [40]. In accordance to our data, Hempen et al. [41] also observed 
that YKL-40 is elevated in morbidly obese patients, and declines after weight loss. However,  
Nielsen et al. [42] found that YKL-40 is an obesity-independent marker of type 2 diabetes. 
Interestingly, the most upregulated gene in the array, HLA-DRB4, has neither been previously 
reported to be expressed in the adipose tissue, nor related with obesity. Due to its role in the immune 
system [43] it can be hypothesized that its different expression might be explained by the infiltration of 
macrophages occurring in obese subjects, although this needs to be clarified in future experiments. 
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Table 2. Differentially expressed genes in subcutaneous abdominal adipose tissue (SCAAT) of obese vs. lean subjects with similar dietary and 
lifestyle habits. 
Gene name Gene symbol 
SLR (Microarray) Lean Obese 
RT-PCR p value 
Mean SD Mean SD Mean SD 
Upregulated 
Activated leukocyte cell adhesion molecule ALCAM 0.73 0.33 1.0 0.2 4.9 3.9 0.048 
Cathepsin B CTSB 0.65 0.45 1.0 0.2 1.8 0.4 0.026 
Complement component 1, S subcomponent C1S 0.58 0.25 1.0 0.2 2.3 0.4 0.003 
Chitinase 3-like 1 (CHI3L1) or human cartilage glycoprotein-39 YKL-40 1.28 0.53 1.0 0.2 1.9 0.4 0.026 
EGF-like-domain, multiple 6 EGFL6 3.13 0.79 1.0 0.2 2.0 0.4 0.015 
Macrophage migration inhibitory factor MIF 0.58 0.10 1.0 0.4 2.8 1.0 0.031 
Palladin PALLD 1.10 0.22 1.0 0.3 2.5 1.7 0.037 
Serum amyloid A2 SAA2 0.93 0.91 1.0 1.8 6.8 4.6 0.020 
Tenomodulin TNMD 1.53 0.56 1.0 0.2 5.0 0.3 0.003 
Downregulated 
Cbp/p300-interacting transactivator CITED2 −1.05 0.26 1.0 0.4 0.3 0.1 0.019 
v-Fos FBJ murine osteosarcoma viral oncogene FOS −2.75 2.10 1.0 0.2 0.9 0.4 0.998 
Nuclear receptor subfamily 3, group C, member 1 NR3C1 −0.90 0.18 1.0 0.2 0.2 0.1 0.028 
The alteration ratios of the gene expression are represented as means of signal log ratio (SLR) of the four quotients (see experimental Section 3.4). Quotients were 
calculated from the gene expression for the obese subjects divided by that of the lean subjects. Differential gene expression was further confirmed by RT-PCR of a subset 
of genes. SD, Standard Deviation; n = 9 in each group. Differences between the lean and obese groups were analysed by the unpaired Student’s t or  
U Mann Whytney’s test after testing the normality with the Kolmogorov-Smirnoff and Shapiro-Wilk tests. 
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It is well known that the expanding adipose tissue during high fat feeding makes a substantial 
contribution to the development of obesity-linked inflammation via dysregulated production of  
pro-inflammatory cytokines (such as TNF-alpha and Interleukin-6) [44], chemokines and adipokines 
and the reduction of anti-inflammatory adipokines (like adiponectin). In this context, we found a 
significant upregulation of IL-6 mRNA (1.00 ± 0.12 vs. 2.82 ± 0.55, p < 0.05) and a downregulation of 
adiponectin [45] in SCAAT of our obese volunteers. This state of chronic low-grade inflammation 
could be powerfully augmented through the infiltration of macrophages into white adipose tissue, 
which perpetuate a proinflammatory vicious cycle [46]. Taking all present data together, it can be 
hypothesized that adipose tissue itself is involved in the chronic activation of relatively nonspecific 
defence system, as other groups have proposed [29,30]. Thus, a genetic background favoring  
a chronic disturbance of the metabolic homeostasis could lead to an upregulation of the 
proinflammatory-related genes, which could underlie the development of the metabolic syndrome. 
2.2.2. Genes Involved in Extracellular Matrix Remodeling 
Cell adhesion (p < 0.01) and proteolysis (p < 0.05) pathways both involved in extracellular matrix 
(ECM) remodeling showed higher mRNA levels of genes encoding for focal adhesion and ECM: 
CTGF, LTBP2, ITGB5, SPON2, MMP9 and WISP2, whereas TIMP4 and PTENP1 two inhibitors were 
downregulated in SCAAT of obese subjects. Interestingly, the expression of genes encoding a range of 
proteins associated with cytoskeletal structure of cells as Transgelin, TUBB2 and PALLD were 
upregulated (Table S1). 
Therefore, obese volunteers showed an upregulation in some extracellular matrix  
remodelation-related genes, a process that is suggested to take place during obesity to accommodate 
adipose tissue expansion, and which seems to be very important in the development of obesity  
and its co-morbidities [47]. Different studies in animals and humans have shown that some  
ECM-related genes are upregulated, such as osteopontin [48]. However, other genes like the MMPs  
(matrix metalloproteinases), seem to be downregulated [49,50]. Furthermore, an upregulation of 
PALLD, a novel actin cytoskeleton-associated protein, essential for cell-ECM interaction through 
maintaining normal actin cytoskeleton architecture [51], was detected. Recently, the possible relation 
of this gene with myocardial infarction [52] and pancreatic cancer [53] has been discarded, but a 
possible link with obesity is still under research. Another group of researchers observed, by DNA 
microarray, an expression of this gene of more than eight fold higher in large adipocytes compared to 
small adipocytes [54]. More information is needed to fully understand these outcomes. 
2.2.3. Genes Involved in Angiogenesis 
Our data show that the expression of several proangiogenic factors was also upregulated (p < 0.05) in 
obese subjects. These factors included EGFL6, Leptin, CTGF and cysteine-rich protein-61 (CYR61) 
(Table S1). In addition, ALCAM [55] and CTSB [56] also involved in inflammatory processes had 
angiogenic activities. 
In this context, accumulating evidence suggests that adipose tissue growth/expansion is dependent 
on angiogenesis and endothelial cell proliferation [57]. Here, we demonstrated that EGFL6, an 
angiogenesis-related gene previously shown to be expressed in human adipose tissue [58], is 
Int. J. Mol. Sci. 2013, 14 17244 
 
 
upregulated in the obese. In addition, CTSB a novel cathepsin member, as CTSK and CTSP previously 
related with inflammation in White Adipose Tissue (WAT) [59,60], which encodes a lysosomal 
protease implicated in degradation of ECM and angiogenesis [61] was upregulated in obese compared 
to lean subjects. Interestingly, CTSB has been found to be overexpressed and more active under hypoxic 
conditions [62], as those suggested to occur in obese patients [5]. However, our data revealed that 
tenomodulin, which is considered a putative angiogenesis inhibitor, was also found to be upregulated 
in obese subjects. This is in agreement with the results from Saiki et al. [63]. Other investigations have 
highlighted the importance of polymorphisms in this gene in the development of obesity and type 2 
diabetes [64], cholesterol metabolism [65] and mild inflammation [66]. Furthermore, Kolehmainen  
et al. [67], suggested that tenomodulin could be involved in extracellular matrix remodeling, and in 
these samples this might be its main role instead of its anti-angiogenic properties. 
2.2.4. Genes involved in Oxidative Stress 
The analysis of the microarray revealed that several genes encoding proteins involved in ROS 
(Reactive oxygen synthesis) activity were overexpressed, such as AKR1C3, UCHL1, HSPB7 and NQO1. 
Oxidative stress is considered one of the main reasons triggering and maintaining the inflammatory 
processes that occur within obesity and related co-morbidities, such as diabetes and cardiovascular 
disease [10,11,68]. The upregulation of AKR1C3, UCHL1 and NQO1 has been linked with obesity 
previously. Thus, AKR1C3, a gene that encodes a member of the aldo/keto reductase superfamily, 
apparently induces androgen inactivation, increasing adiposity [69–71]. Furthermore, central obesity, 
which is more pernicious than peripheral obesity, is associated with overexpression of this gene [71]. 
Additionally, Svensson et al. [72] have shown that diet induced weight loss reduced AKR1C3 mRNA 
levels in human obese subjects, and that larger adipocytes presented higher levels of this gene in 
comparison to smaller adipocytes. Moreover, a deubiquitinating enzyme, Ubiquitin carboxy-terminal 
hydrolase L1 (UCH-L1), seemed to be deficient in humans with type 2 diabetes [73], although it has 
been found overexpressed under hypoxic conditions and in visceral fat from humans modulating 
Peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway [74]. In addition, 
Palming et al. [75] have shown that NQO1 expression, a member of the reduced Nicotinamide 
Adenine Dinucleotide Phosphate (NAD(P)H) dehydrogenase (quinone) family, is increased in human 
adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers 
of liver dysfunction. Furthermore, the use of capsaicin as an antiobesity compound reduced the 
expression of NQO1 in rats [76]. 
Interestingly, HSPB7 a heat shock protein, to our knowledge, has not been linked to obesity, but there 
are several studies reporting its association to cardiovascular disease, although its overexpression seems 
to be protective [77], common variants in this gene have been associated with advanced heart failure [78]. 
2.3. Under-Represented GO Biological Process Categories 
2.3.1. Genes Involved in Apoptosis 
The apoptosis induction pathway was downregulated (p < 0.05), five transcripts encoding proteins 
involved in this inhibited pathway are: RAD21; S100B; RHOB; PLAGL1; CIDEA. 
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2.3.2. Genes in Cell Control and Cell Cycle 
A general downregulation of genes concerning categories of the regulation of cell cycle control/cell 
proliferation, and cell growth and maintenance that might reflect the change in SCAAT from obese 
subjects was found (Table S2). 
2.3.3. Genes in Signal Transcription 
The transcription regulation category included fifteen genes that were downregulated (p < 0.05). 
Interestingly, and contrary to expectations, several genes involved in the JNK (c-Jun N-terminal 
kinases) signal transduction pathway: FOS, FOSB, and JUN (forming the transcription factor complex 
AP-1, activator protein 1) were downregulated. However, the data of the RT-PCR analysis did not 
confirm the FOS downregulation in SCAAT from obese compared to lean. In addition to this, 
Chazenbalk et al. [79] and Jones et al. [80] have recently reported an underexpression of FOS and JUN 
in women with Polycystic Ovary Syndrome, a disease often accompanied by obesity [81,82], agreeing 
with our results found in young male subjects. Moreover, CITED2 a member of the cited family of 
nuclear regulators and NR3C1 were downregulated (Table 2). 
Additional data are given in Tables S1 and S2, which show other interesting upregulated and 
downregulated genes. For instance, a gene importantly upregulated is SVEP1, which has not been 
previously identified in adipose tissue. SVEP1 is a novel cell adhesion molecule that has been shown 
to be expressed throughout the early phases of myogenesis [83] and in cultured osteogenic cells [84]. 
There is no information about the function of SVEP1 in adipose tissue, but it would be interesting to 
address if it has a potential role in adipogenesis in obesity. 
The current study, as others found in the scientific literature [85], has used RNA samples derived 
from adipose tissue for gene expression profile analysis focusing on obesity. This kind of study design 
is distinct from those in which RNA extracts prepared from separated adipocytes and stroma vascular 
cells (SVC) were utilized. However, it is worth noting that a study with Pima Indians, observed a 
similar upregulation of inflammation-related genes in both preadipocytes/stromal vascular cells and in 
adipocytes of adipose tissue from obese Pima Indians, demonstrating that both preadipocytes/SVC and 
adipocytes may play complementary roles in obesity-related inflammation [86,87]. The above-mentioned 
studies reported a NR3C1 downregulation as we found in our study. 
2.4. Association of Gene Expression with Metabolic Syndrome 
Interestingly, 11 genes differentially expressed in the results of this array, such as: ALCAM; CTSB, 
C1S, CITED2, YKL40, EGFL6, MIF, NR3C1, PALLD, SAA2 and TNMD, were found to be correlated 
with some relevant metabolic syndrome features considering all the enrolled subjects as a whole (Table 3). 
For example, gene expression of several transcripts encoding components of the innate immune 
system as C1S and SAA2 a proinflammatory and lipolytic adipokine, were positively associated with 
waist circumference (r = 0.69; p < 0.01, r = 0.71; p < 0.05, respectively). Furthermore, C1S correlated 
negatively with QUICKI (r = −0.51; p < 0.05), and HDL-cholesterol (r = −0.67; p < 0.01);  
and positively with triglycerides (r = 0.71; p < 0.01) and total cholesterol (r = 0.57; p < 0.05). 
Moreover, SAA2 was associated positively with BMI (r = 0.53; p < 0.05). 
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Table 3. Correlation between gene expression and some relevant metabolic syndrome (MS) features. 
MS features 
ALCAM CTSB C1S CITED2 YKL-40 EGFL6 MIF NR3C1 PALLD SAA2 TNMD 
r p r p r p r p r p r p r p r p r p r p r p 
BMI (kg/m2) 0.73 ** 0.61 * 0.42 – −0.51 – 0.53 * 0.17 – 0.25 – −0.69 * 0.46 – 0.53 * 0.51 * 
Waist circumference (cm) 0.71 ** 0.75 ** 0.69 ** −0.52 – 0.35 – −0.02 – 0.66 * −0.49 – 0.56 * 0.71 * 0.34 – 
QUICKI −0.59 * −0.34 – −0.51 * 0.21 – −0.15 – −0.41 – −0.42 – 0.73 * −0.33 – −0.12 – −0.47 – 
Triglycerides (mg/dL) 0.41 – 0.15 – 0.71 ** −0.27 – 0.19 – 0.56 * 0.31 – −0.52 – 0.45 – 0.37 – 0.35 – 
Total-Chol (mg/dL) 0.65 * 0.31 – 0.57 * −0.08 – 0.25 – 0.15 – 0.36 – −0.50 – 0.48 – 0.43 – 0.44 – 
HDL-Chol (mg/dL) −0.68 ** −0.24 – −0.67 ** 0.15 – −0.10 – −0.36 – −0.22 – 0.16 – −0.64 * −0.28 – −0.32 – 
Systolic BP (mmHg) 0.59 * 0.39 – 0.39 – −0.73 ** 0.45 – −0.18 – 0.12 – −0.65 – 0.47 – 0.22 – 0.29 – 
Diastolic BP (mmHg) 0.20 – 0.11 – 0.36 – −0.78 ** 0.47 – 0.25 – −0.11 – −0.42 – 0.37 – 0.32 – 0.09 – 
Spearmann correlation was performed between gene expression (arbitrary units 2−ΔΔCt) and other parameters. * p < 0.05; ** p < 0.01. BMI: Body mass index; insulin 
sensitivity was indirectly determined by the QUICKI model. All the studied subjects were considered as a whole group, n = 18. 
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In addition, the association of several genes related to inflammation: ALCAM, an adhesion  
molecule of the Ig superfamily, which correlates with BMI (r = 0.73; p < 0.01) waist circumference  
(r = 0.71; p < 0.01), QUICKI (r = −0.59, p < 0.05), total cholesterol (r = 0.65; p < 0.05),  
HDL cholesterol (r = −0.68; p < 0.01), and systolic BP (r = 0.59; p < 0.05) was evidenced.  
CTSB a member of the cathepsin family correlated with BMI (r = 0.61; p < 0.05),  
waist circumference (r = 0.75: p < 0.01). These findings involving C1S, SAA2, ALCAM and CTSB are 
novel to the author’s knowledge. 
YKL-40 (also known as CHI3L1), recently defined as a biomarker of inflammation elevated in 
patients with type 2 diabetes and related to insulin resistance, correlates with BMI (r = 0.53; p < 0.05), 
as seen in previous studies [88–90] and in contrast with Nielsen et al. [42]. Furthermore, tenomodulin, 
a member of the cytoskeleton involved in the fibrosis process correlated with BMI (r = 0.51; p < 0.05), 
as found by the group of Carlsson [63]. In this context, it has been observed that an upregulation of 
certain genes in the inflammatory response and cell adhesion molecules promote the recruitment of 
monocytes and other cells, triggering the cardiovascular disease [91]. 
3. Experimental Section 
3.1. Experimental Subjects 
Nine lean (22–33 years old) and nine obese (21–35 years old) male high fat consumers with similar 
physical activity patterns and matched by age were recruited, using a validated questionnaire based on 
self-reported questions about lifestyle and food frequency consumption as previously described [18]. 
In order to confirm that the amount and composition of the energy intake was >40% from fat, each 
subject completed a 3 day weighed food record for two weekdays and one weekend day. The food 
records were analyzed with a computerized program (Medisystem, SanoCare, Madrid, Spain) by a 
trained nutritionist. Physical activity/sedentary lifestyles were assessed (Table 1) through the number 
of hours per week spent sitting down, (watching TV or videos, computer games, reading or listening to 
music, etc.) on a typical work day and on a typical weekend day [92]. 
3.2. Anthropometrical Measurements and Adipose Tissue Biopsy 
On the experimental day, volunteers arrived at the Clínica Universidad de Navarra after 12 h of 
overnight fast. Anthropometrical measurements were made by standard procedures as previously 
described [18]. Then, biopsies of subcutaneous abdominal periumbilical area adipose tissue (1–2 g) 
were performed by liposuction under local anaesthesia following an overnight fast. The samples were 
washed, soaked in RNA-later (Qiagen, Valencia, CA, USA) to avoid RNA degradation and then stored 
at −80 °C until their utilization. The protocol was approved by the Ethical Committee of the University 
of Navarra meeting the standards of the Declaration of Helsinki (Add 1997), and all subjects gave their 
written informed consent before participating in the study. 
3.3. Blood Pressure and Measurements 
Blood pressure (systolic and diastolic) was measured with a standard mercury sphygmomanometer 
(Minimus II, Riester, Germany) as described elsewhere [93]. Fasting blood measurements were made 
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by standard procedures as previously described [18]. The quantitative insulin sensitivity check  
index (QUICKI) was determined using the inverse of the sum of the logarithms of the fasting  
insulin (µU/mL) and fasting glucose (mg/dL). 
3.4. Microarray Analysis 
Total RNA was isolated from each human subcutaneous fat sample as previously described [45]. 
Then, RNA was pooled to minimize the biological variation between the individual lean and obese 
subjects. Thus, 15 µg of total RNA from two pools of three lean subjects (L1 and L2) and two other 
from three obese individuals (O1 and O2) were used in the standard protocol from Affymetrix to label 
targets. These targets (biotinylated complementary RNA were hybridized to the Human HG-U133 A 
GeneChip arrays (Affymetrix, Santa Clara, CA, USA) at Progenika Biopharma Inc (Bilbao, Spain), 
using tools obtained from Affymetrix and according to the manufacturer’s protocol (Affymetrix,  
Santa Clara, CA, USA). Thus, a total of four array hybridizations were performed. 
Differences in expression of individual genes between obese-susceptible and lean-resistant, were 
analyzed using Microarray Analysis Suite (MAS) 5.0 (Affymetrix, Santa Clara, CA, USA). The 
alteration ratios of the gene expression were represented as means of Signal Log Ratio (SLR) of the 
four quotients. Quotients were calculated from the gene expression for the obese subjects divided by 
that of the lean subjects. The “change call” criteria of Affymetrix software for several known genes 
related to obesity matched a call change value of 75% (“increase”: leptin; “decrease”: adiponectin). 
These changes were verified by RT-PCR [45]. For this reason, as a cutoff value, concordance in the 
different call change of 75% or more was chosen in the indications of “increase” and “decrease” for  
obesity-dependent changes, as previously described [94]. Then, the results from MAS were classified 
according to GO biological process criteria [95] and analysis of biological pathways was performed by 
the WebGestalt system [96], which uses the hypergeometric test to identify those pathways in which 
the number of identified genes exceeded the number expected (p < 0.05). Up and downregulated genes 
were analyzed separately. 
3.5. Real-Time PCR Analysis 
Differential gene expression was further confirmed by RT-PCR of a subset of genes from individual 
SCAAT sample cDNA (n = 9 in each group). Reagents for RT-PCR analysis of: Activated leukocyte 
cell adhesion molecule (ALCAM), Cathepsin B (CTSB), Complement component 1, s subcomponent (C1S), 
CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2), YKL-40 (chitinase 3-like 1 (CHI3L1)), 
EGF-like-domain, multiple 6 (EGFL6), v-fos FBJ murine osteosarcoma viral oncogene homolog FOS, 
Tenomodullin (TNMD), macrophage migration inhibitory factor (MIF), Palladin (PALLD),  
serum amyloid A2 (SAA2), nuclear receptor subfamily 3, group C, member 1 (NR3C1) and 18S 
(Assays-on-Demand, TaqMan Reverse Transcriptase reagents, and TaqMan Universal PCR Master mix) 
were purchased from Applied Biosystems (Foster City, CA, USA) and the experimental conditions 
were used according to the manufacturer’s protocol. Amplification and detection of specific products 
were performed with the ABI PRISM 7000HT system (Applied Biosystems). Human 18S was used as 
reference to normalize the expression levels between samples allowing data to be expressed relative to 
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18S rRNA, therefore compensating for any differences in reverse transcriptase efficacy, as  
previously described [45]. 
3.6. Statistical Analysis 
Differences between the lean and obese groups were analysed by the unpaired Student’s t or U Mann 
Whytney’s test after testing the normality with the Kolmogorov–Smirnoff and Shapiro–Wilk tests. The 
Spearman correlation coefficient was used to identify related variables. Statistical analysis was 
performed using the SPSS 15.1 software for Windows (SPSS Inc., Chicago, IL, USA). Values of  
p < 0.05 were considered as statistically significant. 
4. Conclusions 
In summary, we characterized two groups of subjects with different susceptibility to gaining weight 
and developing metabolic syndrome cluster, despite both groups eating a similar amount of fat and 
performing the same level of physical activity. In this context, we suggested that it is not an excessive 
energy intake per se but a genetic background favoring chronic disturbance of metabolic homeostasis, 
which could be behind the upregulation of the proinflammatory/oxidative stress-related genes and 
could underlie a vulnerability to the metabolic syndrome. 
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